The Effect of Intercostal Nerve Block With Dexamethasone and Ropivacaine on Rebound Pain After Thoracoscopic Surgery

Capital Medical University

Status: Not yet enrolling

Conditions: Thoracoscopic Surgery; Intercostal Nerve Block; Rebound Pain; Dexamethasone

Treatments: Drug: Dexamethasone 8mg+0.375% ropivacaine; Drug: 0.375% ropivacaine

Study type: Interventional

Funder types: Other

Identifiers

NCT05825378

20230411

Details and patient eligibility

About

Regional nerve block is one of the commonly used methods for postoperative analgesia after thoracoscopic surgery. Recent studies have found that rebound pain may occur after regional block, which is defined as acute postoperative pain that occurs after the resolution of sensory block related to regional anesthesia, and seriously affects the quality of postoperative recovery of patients. There is evidence that rebound tenderness is associated with local anesthetic toxicity and proinflammatory effects. The aim of this study was to investigate the effect of dexamethasone on rebound pain after a single intercostal nerve block in patients undergoing thoracoscopic surgery.

Enrollment: 260 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients scheduled for elective thoracoscopic surgery Age > 18 years old ASA ⅰ-ⅲ Informed consent was signed

Exclusion criteria

• Patients with aoagulation disorders Patients with allergy to local anesthetics Patients with severe cardiopulmonary diseases Patients had systemic steroid use Patients with chronic pain Patients with uncontrolled diabetes and mental disorders History of drug abuse; Body Mass Index more than 35 kg.m-2 Pregnant or breastfeeding woman.

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

260 participants in 2 patient groups

group dexamethasone

Experimental group

Description:

Dexamethasone 8mg+0.375% ropivacaine

Treatment:

Drug: Dexamethasone 8mg+0.375% ropivacaine

group control

Sham Comparator group

Description:

0.375% ropivacaine

Treatment:

Drug: 0.375% ropivacaine